Month: August 2020

MACAU, Aug. 13, 2020 (GLOBE NEWSWIRE) — Studio City International Holdings Limited (NYSE: MSC), a world-class integrated resort located in Cotai, Macau, today announces that it will furnish its unaudited financial results for the second quarter of 2020 on Form 6-K with the U.S. Securities and Exchange Commission (“SEC”) on Thursday, August 20, 2020.Safe Harbor StatementThis press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Studio City International Holdings Limited (the “Company”) may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in...

OTTAWA, Aug. 13, 2020 (GLOBE NEWSWIRE) — HEXO Corp. (“HEXO”, or the “Company”) (TSX: HEXO; NYSE: HEXO) today announced that it has completed its previously announced at-the-market equity program (the “ATM Program”).  Under the ATM Program, the Company sold an aggregate of 33,921,979 common shares between June 18, 2020 and July 31, 2020 through the Toronto Stock Exchange, the New York Stock Exchange and other marketplaces on which the common shares are listed, quoted or otherwise traded.  The common shares were sold at prevailing market prices for gross proceeds of C$17,248,047 and US$12,751,168, or total gross proceeds of C$34,497,272 after applying applicable US$-C$ exchange rates.Distributions of the common shares through the ATM Program were made pursuant to the terms of an equity distribution agreement dated June 16, 2020 among...

OTTAWA, 13 août 2020 (GLOBE NEWSWIRE) — HEXO Corp (« HEXO », ou la « Société ») (TSX : HEXO ; NYSE : HEXO) a annoncé aujourd’hui avoir conclu son programme de placement d’actions au cours du marché communiqué précédemment (le « programme ACM »). Dans le cadre du programme ACM, la Société a vendu un total de 33 921 979 actions ordinaires entre le 18 juin 2020 et le 31 juillet 2020 par l’entremise de la Bourse de Toronto, la Bourse de New York  et d’autres marchés sur lequel les actions ordinaires sont inscrites, cotées ou négociées. Les actions ordinaires ont été vendues aux prix du marché en vigueur, pour un produit brut respectivement de 17 248 047 $ CA et 12 751 168 $ US, soit un produit brut total de 34 497 272 $ CA après prise en compte des taux de change applicables entre le dollar américain et le dollar canadien.Le...

TORONTO and CAMBRIDGE, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and six months ended June 30, 2020.“Over the course of the second quarter of 2020, the value of our unique discovery and development platform was further evidenced as ProMIS made considerable progress in expanding its portfolio of opportunities across multiple neurodegenerative diseases and also in initiated two new diagnosticprograms.” stated Eugene Williams, ProMIS’ Executive Chairman. “We look forward to continued progress applying our unique technology...

RALEIGH, N.C., Aug. 13, 2020 (GLOBE NEWSWIRE) — Highwoods Properties, Inc. (NYSE: HIW) (the “Company”) announced today the early results of the previously announced cash tender offer (the “Offer”) by Highwoods Realty Limited Partnership, the operating partnership through which the Company conducts its operations (the “Operating Partnership”), for up to an aggregate principal amount of $150,000,000 (the “Tender Cap”) of its outstanding 3.20% Notes due 2021 (the “Notes”).The terms and conditions of the Offer are set forth in the offer to purchase, dated July 30, 2020 (the “Offer to Purchase”). The Offer will expire at 12:00 midnight, New York City time, at the end of August 26, 2020, unless extended or earlier terminated by the Operating Partnership.As of 5:00 p.m., New York City time, on August 12, 2020 (such date and time, the “Early...

Record Revenue: $26 million, a 32% Increase vs. Prior YearNet Income: $4.1 million. an Increase of $3.8 million and Adjusted EBITDA: $8.5 million, an 87% IncreaseCompany Reestablishes Full Year 2020 Guidance:Revenues of $94 million – $97 million;Adjusted EBITDA of $23 million – $26 millionROCHESTER HILLS, Michigan, Aug. 13, 2020 (GLOBE NEWSWIRE) — InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2020.Second Quarter Highlights:Net revenues were $26.0 million, an increase of 32% vs. prior year.Gross profit was $16.0 million, an increase of 41% vs. prior year.Gross margin...

TORONTO, Aug. 13, 2020 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM) (“Wallbridge” or the “Company”) is pleased to report strong gold intersections from Area 51 at its 100%-owned Fenelon Gold Property (“Fenelon” or the “Property”), which further confirm the significant underground, high-grade resource potential of this mineralized environment. Area 51, along with the Main Gabbro, the Tabasco and Cayenne Zones, forms part of a large gold system (“Fenelon gold system”) which is targeted by the Company’s ongoing, fully-funded 100,000-metre 2020 drill program in support of a maiden resource estimate anticipated for mid-2021. The Company today reports final assay results of four surface drill holes (FA-20-139, -143, -145, -148), which are in addition to assay results from holes FA-20-143 and -148 released in Wallbridge...

 –Received Agreement and Positive Input from FDA on Phase 3 Pivotal Clinical Trial Design for VERU-111; Phase 3 Trial Expected to Commence in Q1 2021––VERU-111 Phase 1b Clinical Trial Results Accepted for Presentation at European Society for Medical Oncology 2020 Congress —–Company to Host Investor Conference Call Today at 8 a.m. ET–MIAMI, Aug. 13, 2020 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that net revenues for its fiscal 2020 third quarter ended June 30, 2020 increased to $10.3 million, based on sharply higher U.S. prescription sales of FC2®.Third-Quarter Financial Highlights: Fiscal 2020 vs Fiscal 2019Net revenues increased 6% to $10.3 million...

Highlights for the quarter ended June 30, 2020:Net revenues of $11.1 millionGross Profit of $5.7 million, 51% Gross MarginNew Customer orders of $12.4 millionTwo new customer software license contracts, including first for NXP-based 5G solutionsNew GTM strategy, addition of industry veteran to executive team as Chief Revenue OfficerParsippany, New Jersey , Aug. 13, 2020 (GLOBE NEWSWIRE) — Wireless Telecom Group, Inc. (NYSE American: WTT) (the “Company”) announced today results for the 2020 second quarter ended June 30, 2020.Tim Whelan, CEO of Wireless Telecom Group, Inc., commented, “We are pleased with our second quarter financial results which reflect sequential new order growth of 18.5%, improved gross margins and greater contributions from software revenues. I am also excited to report we signed software agreements with two...

TEL-AVIV, Israel and RALEIGH, N.C., Aug. 13, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. (SIX: COPN) (“Cosmo”) for an exclusive licensing and manufacturing agreement for multiple products. The transaction is expected to close in the coming weeks.Pursuant to the agreement, the companies will co-develop a novel next-generation therapy for the eradication of H. pylori infection. Cosmo is to receive the exclusive European rights to the new drug and will pay RedHill $7 million upon signing of the license agreement and an additional $2 million upon approval in Europe, and 30% royalties. The companies plan to jointly execute clinical trials pursuing simultaneous...